What is the 13F Pro Quality Score for CRIS?

13F Pro ranks CURIS INC (CRIS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRIS's current score at https://13fpro.ai/research/CRIS (free sign-up required for the full ranking).

Where does 13F Pro source CRIS data?

All CURIS INC fundamentals and ownership data come directly from SEC EDGAR. CURIS INC files with the SEC under CIK 1108205. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRIS in?

CURIS INC (CRIS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRIS research updated on 13F Pro?

CRIS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CURIS INC(CRIS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1108205 CRIS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $17.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CRIS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CURIS INC (CRIS), a Healthcare sector company. CRIS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $17.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), CURIS INC reports net income of $-24.2M, free cash flow of $-9.0M. Top institutional holders of CRIS by reported 13-F value include Bleichroeder, Stonepine Capital Management,, Nantahala Capital Management,, based on the most recent SEC filings. CRIS trades on the Nasdaq exchange and files with the SEC under CIK 1108205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRIS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CURIS INC directly from SEC EDGAR. CURIS INC's 13F Pro composite quality score has ranged between 7 and 13 since 2022, currently 10.4 — a stable long-term trajectory across 11 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-24.2M

Free Cash Flow

Q1 2026

$-9.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-13.4% YoY

$9.4MFY 2025

FY20 $10.8MFY22 $10.2MFY24 $10.9MFY25 $9.4M

Net Income

+82.5% YoY

$-7.6MFY 2025

FY20 $-29.9MFY22 $-56.7MFY24 $-43.4MFY25 $-7.6M

Operating Income

+87.2% YoY

$-5.7MFY 2025

FY20 $-24.9MFY22 $-53.0MFY24 $-44.5MFY25 $-5.7M

EPS (Diluted)

+91.6% YoY

$-0.19FY 2025

FY20 $-0.61FY22 $-4.05FY24 $-2.29FY25 $-0.19

Total Assets

-51.6% YoY

$20.0MFY 2025

FY20 $204.4MFY22 $108.8MFY24 $41.3MFY25 $20.0M

Total Debt

-100.0% YoY

$0.00FY 2025

FY20 $891.0KFY22 —FY24 $7.6MFY25 $0.00

Op. Cash Flow

+31.2% YoY

$-27.2MFY 2025

FY20 $-25.7MFY22 $-54.3MFY24 $-39.6MFY25 $-27.2M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2018	FY 2014
Revenue	$9.4M -13.4%	$10.9M +7.3%	$10.2M -6.2%	$10.8M +3.9%	$10.4M +5.9%	$9.8M
Net Income	$-7.6M +82.5%	$-43.4M +23.4%	$-56.7M -89.5%	$-29.9M +8.2%	$-32.6M -73.9%	$-18.7M
Operating Income	$-5.7M +87.2%	$-44.5M +16.0%	$-53.0M -112.9%	$-24.9M +15.1%	$-29.3M -84.9%	$-15.9M
EPS (Diluted)	$-0.19 +91.6%	$-2.29 +43.3%	$-4.05 -563.4%	$-0.61	—	—
Total Assets	$20.0M -51.6%	$41.3M -62.1%	$108.8M -46.7%	$204.4M +446.9%	$37.4M -40.3%	$62.6M
Total Debt	$0.00 -100.0%	$7.6M	—	$891.0K -97.9%	$42.4M +49.8%	$28.3M
Operating Cash Flow	$-27.2M +31.2%	$-39.6M +27.2%	$-54.3M -111.1%	$-25.7M +14.4%	$-30.1M -78.8%	$-16.8M

AI Insight: CRIS Financial Trends

Curis swung to a $19M net profit in Q4 2025 but collapsed back to a $24M loss in Q1 2026, signaling unsustainable earnings volatility.

• Operating losses narrowed from $13M in Q2 2024 to $7M in Q3 2025, then turned $20M positive in Q4 2025 before reversing to $12M negative in Q1 2026.

• Revenue flat-to-declining: $3M in Q2–Q3 2025 and Q2 2024, collapsed to $0M in Q1 2026. No growth trajectory evident.

• Operating cash flow consistently negative across all eight quarters, ranging $6M–$11M burn. Q1 2026 outflow: $9M.

⚠ Q4 2025 $19M net income appears non-cash or one-time; immediate reversion to $24M loss in Q1 2026 raises sustainability concerns.

⚠ Equity swung from negative $15M in Q3 2025 to positive $13M in Q1 2026—likely capital raise. Debt cleared to $0M, but burn continues.

AI Insight: CRIS Ratio Trends

Curis is deeply unprofitable with massively negative returns; TTM operating margin of -100.2% and ROA of -71.3% reflect severe cash burn with minimal financial visibility.

• Operating margin at -100.2% (TTM ending Q1 2026) indicates losses exceed revenue; no improvement trajectory visible across available data.

• ROA deteriorated from -93.2% (Q4 2024) to -71.3% (TTM Q1 2026), suggesting asset efficiency remains severely impaired.

• D/E ratio at 0.00 (Q4 2025) indicates minimal debt, a rare bright spot for a cash-burning biotech.

⚠ Minimal quarterly data disclosure (Q1–Q3 2025 ratios blank) obscures recent operational performance and cash runway.

⚠ Negative ROIC of -55.7% (TTM) signals value destruction; monitor for clinical inflection or funding events.

Get alerted when CRIS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CURIS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRIS

Bleichroeder LP
$2.1M3,802,329 sh
Stonepine Capital Management, LLC
$2.0M3,726,406 sh
Nantahala Capital Management, LLC
$1.1M2,000,000 sh
SPHERA FUNDS MANAGEMENT LTD.
$1.1M1,994,937 sh
Cable Car Capital, LP
$729.7K1,333,334 sh
Dauntless Investment Group, LLC
$362.3K658,725 sh
VANGUARD CAPITAL MANAGEMENT LLC
$204.8K374,326 sh
RENAISSANCE TECHNOLOGIES LLC
$200.7K366,740 sh
M28 Capital Management LP
$155.9K284,889 sh
MORGAN STANLEY
$139.1K254,245 sh

Fund	Value	Shares
Bleichroeder LP	$2.1M	3,802,329
Stonepine Capital Management, LLC	$2.0M	3,726,406
Nantahala Capital Management, LLC	$1.1M	2,000,000
SPHERA FUNDS MANAGEMENT LTD.	$1.1M	1,994,937
Cable Car Capital, LP	$729.7K	1,333,334
Dauntless Investment Group, LLC	$362.3K	658,725
VANGUARD CAPITAL MANAGEMENT LLC	$204.8K	374,326
RENAISSANCE TECHNOLOGIES LLC	$200.7K	366,740
M28 Capital Management LP	$155.9K	284,889
MORGAN STANLEY	$139.1K	254,245

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRIS on your watchlist

Track score changes the day CURIS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRIS a good stock to buy?

13F Pro's AI-powered analysis of CURIS INC (CRIS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRIS are available on the CRIS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRIS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRIS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CURIS INC's investment landscape.